Bioavailability study of dried microencapsulated ferrous sulfate--SFE 171--by means of the prophylactic-preventive method.
Microencapsulated ferrous sulfate with soy lecithin (SFE-171) has been used as an iron source for the fortification of milk and dairy products. With the purpose to extend the use of this agent to other kind of foods or even to pharmaceutical preparations for oral administration, the SFE-171 was turned into a fluid powder (SFE-171-P) by means of vacuum drying. The iron bioavailability (BioFe) of SFE-171-P was evaluated in this work by means of the prophylactic-preventive method in rats, using ferrous sulfate as reference standard. Both iron sources were separately added to a basal diet of low iron content in a concentration of 10 mg iron/kg diet. Two groups of 10 weaned rats 25 days old received the fortified diets during 28 days, while a third group of the same size received the basal diet without iron additions. The weights and haemoglobin concentrations (HbC) of every animal were determined before and after the treatment, thus allowing the calculation of the mass of iron incorporated into haemoglobin (HbFe) during this period. The BioFe of the iron sources were obtained as the percentage ratio between the HbFe and the mass of iron consumed by each animal. The results were also given as Relative Biological Value (RBV), which relates the BioFe of the studied source with that of the reference standard. The liver iron concentration (LIC) of each animal was determined at the end of the experiment in order to evaLuate the influence of the studied iron sources on the liver iron stores. SFE-171-P presented BioFe, RBV and LIC values of (47 +/- 7)%, 109% and (46.6 +/- 3.4) mg/kg respectively, while the corresponding values for the reference standard were of (43 +/- 7)%, 100% and (45.0 +/- 4.7) mg/kg. These results show that the drying process used to produce the SFE-171-P does not affect its bioavailability, which is also adequate for the potential use of this product in food fortification or with pharmaceutical purposes.
Lysionek
A E
AE
Radioisotope Laboratory, School of Pharmacy and Biochemistry, University of Buenos Aires, Argentina. aelysionek@huemul.ffyb.uba.ar
Zubillaga
M B
MB
Salgueiro
M J
MJ
Caro
R A
RA
Weill
R
R
Boccio
J R
JR
D000818:Animals; D002624:Chemistry, Clinical / Q000379:methods; D019587:Dietary Supplements; D004305:Dose-Response Relationship, Drug; D004339:Drug Compounding; D005260:Female; D005296:Ferrous Compounds / Q000493:pharmacokinetics*; D006454:Hemoglobins / Q000378:metabolism; D007501:Iron / Q000493:pharmacokinetics*; D010713:Phosphatidylcholines / Q000493:pharmacokinetics*; D051381:Rats; D017207:Rats, Sprague-Dawley
D005296:Ferrous Compounds; D006454:Hemoglobins; D010713:Phosphatidylcholines; C463359:SFE-171; C020748:ferrous sulfate; D007501:Iron